Clinical trials: Coronary Stent Occlusion
Coronary Artery Disease, Atherosclerosis
MASCOT - Post Marketing Registry
To collect post marketing surveillance data on patients receiving at least one Combo Bio-Engineered Sirolimus Eluting Stent when used according to the Instructions for Use.
- Trial name
- MASCOT (NCT02183454)
- Testing
- OrbusNeich COMBO stent
- Where
- Netherlands
- Volunteers
- 2,500 people
- Sponsor
- OrbusNeich
Coronary Artery Disease, Myocardial Ischemia
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
Prospective, randomised, open-label, international multicenter trial to evaluate the safety and efficacy of drug-coated balloon (DCB) treatment compared to drug-eluting stenting (DES) in patients with large coronary artery…
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Coronary Stenosis
- Trial name
- REVERSE (NCT05846893)
- Testing
- SeQuent® Please NEO drug-coated balloon catheter, Current-generation drug-eluting stent
- Where
- 21 sites in Malaysia, Singapore and 2 more
- Volunteers
- 1,436 people
- Sponsor
- B. Braun Medical Industries Sdn. Bhd.
Coronary Artery Disease, Coronary Stenosis
SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis
BACKGROUND: Bifurcated lesions are a challenging subset in percutaneous coronary interventions (PCI). The selection of the type of DES and the technique for stent implantation have not been clarified.
- Trial name
- SEA-SIDE (NCT00697372)
- Testing
- Sirolimus eluting stent, Everolimus eluting stent
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Catholic University of the Sacred Heart
Coronary Artery Disease
Clopidogrel/Aspirin Interaction Study
This study will explore the effect of different doses of aspirin on the effects of double-dose or standard dose clopidogrel.
- Trial name
- INTERACTION (NCT01102439)
- Testing
- Clopidogrel, Aspirin
- Where
- Canada
- Volunteers
- 82 people
- Sponsor
- Population Health Research Institute
Coronary Disease, Coronary Artery Disease
ABSORB Clinical Investigation, Cohort B
The purpose of this study is to assess the safety and performance of the BVS Everolimus Eluting Coronary Stent System (EECSS) in the treatment of patients with a maximum of two de novo native coronary artery lesions located in…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- ABSORB B (NCT00856856)
- Testing
- Bioabsorbable Everolimus Eluting Coronary Stent
- Where
- 12 sites in Australia, Belgium and 6 more
- Volunteers
- 101 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Nordic Bifurcation Stent Technique Study (BIF II)
This is a study of crush- or culotte stenting of bifurcation lesions using drug eluting stents. This is a randomized Nordic multicenter study including 400 patients with angina pectoris with clinical angiographic follow-up.
- Trial name
- BIF II (NCT00292305)
- Testing
- Percutaneous coronary intervention
- Where
- Denmark
- Volunteers
- 425 people
- Sponsor
- Aarhus University Hospital Skejby
Coronary Artery Disease, Myocardial Ischemia
Safety and Efficacy Study of the Amaranth Medical MAGNITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT III)
The purpose of this study is to evaluate the safety and performance of a new version of a coronary artery stent for treating blockages in the arteries supplying blood to the heart muscle.
- Trial name
- RENASCENT III (NCT02900937)
- Testing
- AmM MAGNITUDE Bioresorbable Drug-Eluting Coronary Scaffold
- Where
- 13 sites in Colombia, Italy
- Volunteers
- 70 people
- Sponsor
- Amaranth Medical Inc.
Coronary Artery Disease
DESyne X2 Post Market Follow-up Study
A single-arm post-market clinical follow-up study to confirm that the DESyne X2 delivery system performs similarly to the DESyne delivery system.
- Trial name
- NCT04375085
- Testing
- Percutaneous Coronary Intervention
- Where
- 3 sites in China
- Volunteers
- 49 people
- Sponsor
- Elixir Medical Corporation
Coronary Artery Disease
Treatment of Coronary ARtery bIfurcation Narrowing by AXxess Stent Implantation
The Axxess™ Biolimus A9™ Eluting Coronary Bifurcation Stent System (AXXESS System; Biosensors, International, Morges, Switzerland) is a dedicated bifurcation stent, designed to cover the lesion at the level of the carina.
- Trial name
- CARINAX (NCT02486315)
- Testing
- AXXESS stent
- Volunteers
- 326 people
- Sponsor
- Clinica Mediterranea
Coronary Artery Disease
Study to Evaluate the Safety of Cronus® - Cobalt Chromium Coronary Stent
The objective this study is evaluate the performance and safety of Chronus® cobalt-chromium coronary stent in patients with "de novo" native coronary artery lesions treated with 19-mm-long stents in long-term 9 months.
- Trial name
- CRONUS (NCT01090609)
- Testing
- Stent implantation
- Where
- 13 sites in Brazil
- Volunteers
- 263 people
- Sponsor
- Scitech Produtos Medicos SA
Coronary Artery Disease
Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
The purpose of the study is to assess the safety and efficacy of the Orsiro® Mission 48- mm Sirolimus-Eluting Coronary Stent System in the treatment of subjects with atherosclerotic lesion(s) >36 mm and ≤ 44 mm in length (by…
- Trial name
- BIOFLOW-48 (NCT06779630)
- Testing
- Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System
- Where
- 23 sites in United States, Austria and 4 more
- Volunteers
- 150 people
- Sponsor
- Teleflex
De Novo Stenosis, Coronary Artery Disease
Paclitaxel-coated Balloon for Treatment of De-novo Non-complex Coronary Artery Lesions
The introduction of Bare-metal stents (BMS) since 1986 has alleviated the limitations of plain old balloon angioplasty (POBA) related elastic recoil and flow-limiting dissections.
- Trial name
- NCT04561739
- Testing
- Paclitaxel coated balloon, Sirolimus eluting stents
- Where
- China
- Volunteers
- 2,272 people
- Sponsor
- Xijing Hospital
Coronary Artery Disease
REVEAL Study: Vessel Healing After Angioplasty
To address early vessel healing and thrombus formation after deployment of three distinct groups of stents
- Trial name
- REVEAL (NCT00799344)
- Testing
- Catania Stent
- Where
- Italy
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- CeloNova BioSciences, Inc.
Coronary Artery Disease, In-stent Restenosis
To Study and Explore the Predictive Effect of Insulin Resistance-related Indicators on In-stent Restenosis After Coronary Stent Implantation
Based on previous studies on insulin resistance and cardiovascular diseases, we believe that the insulin resistance metabolic score also has certain predictive value for the prognosis of in-stent restenosis after coronary stent…
- Trial name
- NCT07614763
- Testing
- Observational studies do not design intervention measures
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Qilu Hospital of Shandong University
Coronary Artery Disease, Percutaneous Coronary Intervention
Xience Registry In Complex Lesion of Acute Coronary Syndrome Patients witH Ticagrelor (RICH)
The goal of this multicenter prospective clinical cohort study is to investigate the impact of early use of low-dose Ticagrelor-based dual antiplatelet agent therapy (TDAPT) (ticagrelor 120mg daily; l-TDAPT) as compared to…
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome
- Trial name
- RICH (NCT05746416)
- Where
- South Korea
- Volunteers
- 977 people
- Sponsor
- Hanyang University Seoul Hospital
Coronary Artery Disease, Angina Pectoris
Sirolimus-eluting Stents With Biodegradable Polymer Versus an Everolimus-eluting Stents
Coronary artery stents have improved the safety and efficacy of percutaneous coronary intervention for coronary artery disease. Drug-eluting stents have been shown to decrease neointimal hyperplasia and to reduce the rate of…
- Conditions
- Coronary Artery Disease, Angina Pectoris, Myocardial Infarction
- Trial name
- NCT01443104
- Testing
- Sirolimus-eluting stent with a bioresorbable polymer (Orsiro), Everolimus-eluting stent with a durable polymer
- Where
- 9 sites in Switzerland
- Volunteers
- 2,119 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Coronary Artery Disease
CCTA and Dynamic CT Perfusion for the Diagnosis of Myocardial Ischemia in Patients With Coronary Stents
A single centre prospective trial in which patients with a prior PCI for stable CAD who are referred for invasive angiography will undergo state-of-the art CCTA and dynamic CT perfusion.
- Trial name
- PACIFIC-III (NCT04742933)
- Testing
- There is no intervention in this observational trial
- Where
- Netherlands
- Volunteers
- 140 people
- Sponsor
- Amsterdam UMC, location VUmc
Coronary Artery Disease
Clinical Investigation of the MiStent Drug Eluting Stent (DES) in Coronary Artery Disease
The DESSOLVE II clinical trial is to assess the safety and performance of the sirolimus-eluting MiStent for the treatment for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete…
- Trial name
- DESSOLVE-II (NCT01294748)
- Testing
- MiStent DES, Endeavor DES
- Where
- 28 sites in Belgium, France and 4 more
- Volunteers
- 184 people
- Sponsor
- Micell Technologies
Coronary Artery Disease, Atherosclerosis, Coronary
Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
The objective of this post-approval study is to confirm that the clinical performance of the Orsiro stent in a real-world setting is similar to the clinical performance observed for Orsiro in the BIOFLOW-V Investigational Device…
- Conditions
- Coronary Artery Disease, Atherosclerosis, Coronary, Myocardial Ischemia, Ischemic Heart Disease
- Trial name
- BIOFLOW-VII (NCT04175626)
- Testing
- Orsiro DES
- Where
- 33 sites in United States
- Volunteers
- 556 people
- Sponsor
- Biotronik, Inc.
Coronary Artery Disease
Bivalirudin Plus Stenting in Long Lesion to Avoid Periprocedural Myocardial Necrosis Trial
Background: Randomized trials show improved outcomes among acute coronary syndrome (ACS) patients treated with Bivalirudin1. Optimal antithrombotic treatment in patients undergoing percutaneous coronary intervention (PCI) is…
- Trial name
- BILLION (NCT01555658)
- Testing
- Bivalirudin, Unfractioned Heparin
- Where
- Italy
- Volunteers
- 204 people
- Sponsor
- University of Roma La Sapienza